B
Bull
Bull · 25%ROIV
$12.69
Scenario price
$34.040
+0.426 (+1.25%)At close
Loading chart…
- High
- 34.350
- Open
- 34.000
- VWAP
- 34.03
- Volume
- 4.50M
- Mkt Cap
- 7.81B
- Low
- 33.705
- Amount
- 153.26M
- EV/EBITDA, TTM
- -0.22
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
AI analysis of Roivant Sciences Ltd (ROIV)
BuyRoivant Sciences Ltd is a good buy right now due to its recent positive Phase 2 trial results for mosliciguat, which showed a 56.3% improvement in pulmonary vascular resistance, leading analysts to raise their price targets significantly. The current price of $35.44 is well below the average analyst target of $50 to $55, indicating substantial upside potential. However, the company has faced negative earnings with a net income of -265,891,000 USD in Q3 2026, which poses a risk to investors.
Valuation Metrics
The current forward P/E ratio for Roivant Sciences Ltd (ROIV) is 0.00, compared to its 5-year average forward P/E of -8.04.
Alphio AI Price Scenarios for ROIV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ROIV
Events Timeline
News
5.010-08stocktwitsIMVT-1402 Study Failure Triggers Market Reaction
6.009-17CNBCWall Street's Latest Rating Changes Overview
2.009-09stocktwitsDell, Roivant, and Shell Stocks Hit Record Highs
9.509-08stocktwitsRoivant and Pharvaris Achieve Clinical Trial Success
9.509-08Yahoo FinanceBiotech Stocks Hit All-Time Highs Following Positive Trial Results
ROIV FAQ — answered by Alphio AI
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Roivant Sciences Ltd is a good buy right now due to its recent positive Phase 2 trial results for mosliciguat, which showed a 56.3% improvement in pulmonary vascular resistance, leading analysts to raise their price targets significantly. The current price of $35.44 is well below the average analyst target of $50 to $55, indicating substantial upside potential. However, the company has faced negative earnings with a net income of -265,891,000 USD in Q3 2026, which poses a risk to investors.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.